Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 9/20 | 0.64 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.64 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.64 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | FLT3 | P36888 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015499 | 0.89 | RAF1 (0.52) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL769245 | 0.87 | RAF1 (0.50) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1015351 | 0.87 | RAF1 (0.50) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11293751 | 0.87 | RAF1 (0.50) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL770045 | 0.87 | RAF1 (0.50) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4903102 | 0.86 | RAF1 (0.48) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1011493 | 0.86 | RAF1 (0.49) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL17732309 | 0.86 | RAF1 (0.49) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1012213 | 0.85 | RAF1 (0.48) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL13611455 | 0.84 | RAF1 (0.50) | RAF1MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724439-A1 | HETEROARYL DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2026-04-15 | — | — | EP | disclosed |
| EP-4662206-A1 | GSPT1 DEGRADER COMPOUNDS | Captor Therapeutics S.A. (PL) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024251855-A1 | HETEROARYL DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-12-12 | — | — | WO | disclosed |
| US-12115152-B2 | Pan-RAF kinase inhibitor and use thereof | Tarapeutics Science Inc. (CN) | 2024-10-15 | — | — | US | disclosed |
| US-12091413-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2024-09-17 | — | — | US | disclosed |
| WO-2024165577-A1 | GSPT1 DEGRADER COMPOUNDS | CAPTOR THERAPEUTICS S.A. (PL) | 2024-08-15 | — | — | WO | disclosed |
| EP-4146348-B1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | disclosed |
| EP-1436265-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1432714-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1425284-A2 | FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2004043379-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003072541-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003029209-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-0144098-A1 | Cyclic ureas of isoxazole | SHIONOGI & CO., LTD. (JP) | 1985-06-12 | — | — | EP | disclosed |
| EP-0114456-A2 | Acylated isoxazolyl ureas, their preparation, herbicidal formulations containing the same, and a herbicidal method | SHIONOGI & CO., LTD. (JP) | 1984-08-01 | — | — | EP | disclosed |
| EP-0044185-A2 | Imidazolidinone derivatives | ELI LILLY AND COMPANY (US) | 1982-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091413-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | RAF1 274/4885MAPK13 409/4885MAPK12 713/4885 |
| US-12115152-B2 | Pan-RAF kinase inhibitor and use thereof | BRAF, RAF1, ARAF | RAF1 2/4885MAPK13 36/4885MAPK12 71/4885 |
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | RAF1 944/4885MAPK13 670/4885MAPK12 1037/4885 |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | RAF1 274/4885MAPK13 409/4885MAPK12 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.